Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma - Wikidata - awgldk - TriplyDB

Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma

Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma

http://www.wikidata.org/entity/Q33669018

about

Noxa/Bcl-2 protein interactions contribute to bortezomib resistance in human lymphoid cells Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG).Bortezomib may be safely combined with Y-90-ibritumomab tiuxetan in patients with relapsed/refractory follicular non-Hodgkin lymphoma: a phase I trial of combined induction therapy and bortezomib consolidation.Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study.Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma.Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma.Weekly versus biweekly bortezomib given in patients with indolent non-Hodgkin lymphoma: A meta-analysis Targeted therapy in lymphoma.The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma.Update on treatment of follicular non-Hodgkin's lymphoma: focus on potential of bortezomib Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia.Arsenic trioxide rewires mantle cell lymphoma response to bortezomib Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601.Bortezomib for the treatment of non-Hodgkin's lymphoma Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia.Current treatment of mantle cell lymphoma: results of a national survey and consensus meeting.Controlled-release oxycodone for the treatment of bortezomib-induced neuropathic pain in patients with multiple myeloma.The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphoma.Novel agents in indolent lymphomas.Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma.Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations.Proteasome inhibitors in cancer therapy.

P2860

Q24298561-97811807-ECBA-4A1B-973D-38879C1E8A58 Q33391725-F45CB2D1-D082-40C0-836B-4140EF7679B7 Q33402885-1A1B1325-E1CA-4D9F-BE1A-370F1B37A2AB Q33404090-B676F467-0E14-4CBE-AECD-CBB340BE1B73 Q33416533-104F0F76-64AF-4815-B0F1-B0A1C7367E84 Q33418257-359F2339-8AAB-440F-8960-374B36B3417B Q33713106-30A411C8-1C6D-44E3-8DE3-27C18EE29CED Q34413686-5E1622D1-691E-4CB1-A94E-5B925B460701 Q34707136-724B21D4-0905-409E-B2DF-C2E23083B6E3 Q35009005-8DC9E2FB-FD83-4E6A-B539-6D7F0F60C7A6 Q35905929-8A62EFD5-A7C3-4BB0-9D3E-2E4A57DB3512 Q36057877-30A139A0-F0D1-44F9-984F-F84EEF28C750 Q36358595-B1467A0F-93F3-471C-AA86-9D9175AEC128 Q36456078-B2CC52A7-D47D-42FD-A1F8-2D827B22954B Q36868056-A46417E1-5A63-40FD-8C2E-CE4210123333 Q37587057-FCD70260-91C6-46B0-AAF5-346BB58C6DF6 Q38038482-BEB2DD19-B7E4-497C-9B51-DE5F0C8E6AE6 Q39246290-AA19C7A2-3380-442A-941A-490655D75899 Q39414811-A557CE76-3015-4312-879E-516F1D2200F9 Q39431412-944854B0-FF7F-45D6-A618-B20A02C79034 Q40333043-42AA80B8-165D-4CE1-B6D9-94BD1AA318B0 Q48238170-17CF28E4-B11B-451F-9ABC-1D7100F7277D Q53752929-B4BD349B-796A-407D-BE73-B60EEC5451F7

P2860

Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma

http://www.wikidata.org/entity/Q33669018

description

2009 nî lūn-bûn

@nan

2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

name

Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma

@ast

Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma

@en

type

label

Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma

@ast

Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma

@en

prefLabel

Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma

@ast

Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma

@en

P1433

Q33669018-D484EAB4-8D71-4D0D-A9BA-D90571886027

P1476

Q33669018-834A97EB-F620-44BA-B7D1-FE4FC7F8F26A

P2093

Q33669018-0C331868-A2AE-40E3-949E-895ECD769D69

Q33669018-0CCA1851-4EE4-40B1-B6F4-552D47774D26

Q33669018-22C0A468-3EFF-48A9-9D7B-F2FCC1F39646

Q33669018-26840962-A1AC-434C-8A4F-3B02C9F92973

Q33669018-398FF982-B4B9-4FB0-8CFC-43E9D8CC364E

Q33669018-4C8FDA96-454A-4809-BAD2-C4EFD7692437

Q33669018-5C025E08-1DDD-4E02-8B72-D6701A3BDA4C

Q33669018-834AA655-4227-43F6-BED3-450BA37963CD

Q33669018-87BE30D8-0A81-4342-A869-FD03C202E8BF

Q33669018-8EED9A02-4A13-4DF3-B8C2-09775F9DE054

P2860

Q33669018-0D1D1363-DEDE-4B6A-8BE9-DD8296341ED0

Q33669018-17FB8EB5-B024-4E85-80FF-36DE4A3348E1

Q33669018-51D98D87-5EA4-4257-8DDC-5F320BFDC77D

Q33669018-7DD60155-E5FE-45E5-879D-C931123A5219

Q33669018-B0F75805-21F0-4887-9725-4BCE7CB57F64

Q33669018-B5741E81-DF61-4CDB-8584-78E9DBBCFF46

Q33669018-B7FDB435-09DD-44FC-90FF-339A7B459006

Q33669018-C0C55E89-A1BE-47AC-B84E-87ED9A9F10BD

Q33669018-C6E52D56-8362-43D4-844E-7A89CCBFBD93

Q33669018-CF755D1C-0583-41A0-B4CF-4DFB85C43EAD

P304

Q33669018-2212D6D7-79C4-49C1-98E6-17C6D80316BD

P31

Q33669018-110EACAD-8D4E-4B31-BF7E-2CACAAF3084F

P356

Q33669018-F010B339-73AD-4701-A06A-65E229BD96B9

P407

Q33669018-E0F97E12-208F-4F53-AB39-CF2F84E392A4

P433

Q33669018-CDE00C13-6AC3-47DD-8692-F344CB1B77F7

P478

Q33669018-9ACC8DF6-B68C-4439-859C-5D6CCFB7F36D

P50

Q33669018-892376DF-795A-474D-8FA9-D70673EF3F5C

Q33669018-C3EF6209-9FA7-46E5-B958-63AB2585C7CE

Q33669018-C6C94F66-CA51-4ACC-8A27-AE31EE2382C2

Q33669018-F13E1923-9481-4266-B928-265453E33A8D

P577

Q33669018-CF302577-E7C0-46C9-AA7E-F67B792CDCA5

P5875

Q33669018-79B3109F-899D-425E-8419-8D98FE8A74A5

P698

Q33669018-59FB6E5E-EA1E-4488-822D-1843A2860771

P932

Q33669018-6FDE3383-397C-493E-84DF-2992724A82EC

P356

J.1365-2141.2009.07775.X

P1433

British Journal of Haematology

P1476

Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma

@en

P2093

Barbara M Cortelli

http://www.w3.org/2001/XMLSchema#string

Carol Portlock

http://www.w3.org/2001/XMLSchema#string

Craig Moskowitz

http://www.w3.org/2001/XMLSchema#string

David Straus

http://www.w3.org/2001/XMLSchema#string

Dorothy Lin

http://www.w3.org/2001/XMLSchema#string

Ellen Neylon

http://www.w3.org/2001/XMLSchema#string

Jennifer Pappanicholaou

http://www.w3.org/2001/XMLSchema#string

John Gerecitano

http://www.w3.org/2001/XMLSchema#string

John Wright

http://www.w3.org/2001/XMLSchema#string

Otilia Dumitrescu

http://www.w3.org/2001/XMLSchema#string

P2860

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.

Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity.

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.

Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network.

Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes.

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies.

Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.

Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.

P304

652-655

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2141.2009.07775.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

146

http://www.w3.org/2001/XMLSchema#string

P50

Andrew D Zelenetz

Debra M Sarasohn

Rachel Hamelers

P577

2009-07-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26688036

http://www.w3.org/2001/XMLSchema#string

P698

19624539

http://www.w3.org/2001/XMLSchema#string

P932

4035037

http://www.w3.org/2001/XMLSchema#string